
The goal in selecting investments is to work with luminaries in the field of type 1 research to move ideas out of the laboratory and onto the road to real patients. About four people will run the fund at PureTech, with lots of input from Breakthrough T1D leaders, including renowned entrepreneur CEO Jeffrey Brewer.